APAC Infusion Pumps Market

The APAC infusion pumps market is dominated by Becton, Dickinson and Company (US), B. Braun Melsungen AG (Germany), Fresenius Kabi (Germany), Baxter International (US), and Medtronic PLC (Ireland).

The APAC infusion pumps market is expected to reach USD 5.7 billion by 2027 from an estimated USD 3.7 billion in 2022, at a CAGR of 9.1%. The rising demand for ambulatory infusion pumps in homecare settings, increasing incidence of chronic diseases along with the rapid growth of the geriatric population, increasing adoption of enteral feeding pumps with surge in pre-term births, growing number of surgical procedures performed, and increasing number of ICU beds in countries with a high prevalence of COVID-19 are some of the key factors driving the growth of the APAC infusion pumps market. However, the presence of stringent regulations for new products, medication errors associated with infusion pumps (which have resulted in product recalls), and the increasing adoption of refurbished and rental infusion pumps are expected to restrain the growth of this market during the forecast period.

The APAC infusion pumps market is highly competitive. Some of the major players governing the APAC infusion pumps market include Becton, Dickinson and Company (US), B. Braun Melsungen AG (Germany), Fresenius Kabi AG (Germany), Baxter International, Inc. (US), Medtronic PLC (Ireland), ICU Medical, Inc. (US), Avanos Medical, Inc. (US), Terumo Corporation (Japan), Nipro Corporation (Japan), JMS Co., Ltd. (Japan), Cardinal Health, Inc. (US), Epic Medical (Singapore), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories(US), and Danaher Corporation(US).

To know about the assumptions considered for the study download the pdf brochure

Becton, Dickinson and Company (US) is the leader in the APAC infusion pumps market. The company offers a wide range of products, including volumetric pumps, syringe pumps, and PCA pumps, under its market-leading brand—Alaris. The company also provides dedicated disposables and non-dedicated accessories for infusion products. Over the years, the company has maintained its leading position in the market through continuous innovation and the launch of advanced products. BD consistently improves its product offerings by enabling its infusion products to be ready for data integration with other allied products. BD also collaborates with universities, medical centers, and other entities to conduct R&D programs to support its efforts in specialized fields. The company’s R&D expenditure during 2021, 2020, and 2019 was estimated at USD 1,339.0 million, USD 1,096.0 million, and USD 1,062.0 million respectively.

B. Braun Melsungen AG (Germany) held the second position in the APAC infusion pumps market in 2021. B. Braun offers a wide range of infusion pumps and accessories. Over the years, the company has gained a greater market share through significant investments in expanding its geographic reach. For instance, in April 2018, the company opened five new medical production facilities in Penang, Malaysia. These new facilities will manufacture medical devices for infusion therapy, pharmaceutical solutions, and surgical instruments to treat patients in Malaysia and across the globe.

B. Braun has a strong presence in about 64 countries across North America, Europe, the Asia Pacific, Africa, the Middle East, and Latin America. It has 262 consolidated companies across the globe. The firm’s major manufacturing sites are in Germany, Brazil, China, France, India, Malaysia, Poland, Switzerland, Spain, and Hungary.

Fresenius Kabi AG (Germany) held the third position in the APAC infusion pumps market in 2021. The company operates through four business segments, namely, IV Drugs, Clinical Nutrition, Medical Devices/Transfusion Technology (TT), and Infusion Therapy. The company offers infusion pumps and related accessories through the Medical Devices/Transfusion Technology (TT) segment. The company production facilities in more than 90 countries across the globe.

Fresenius Kabi’s leadership in the market can be attributed to its efficient sales network and expansion strategies. The company focuses on lunching of new products to improve its product portfolio. In this regards, in 202, the company launched the Exillia Infusion Pump to cater to the increasing demand during the COVID-19 pandemic. The company’s R&D expenditures were USD 704.0 million in 2021, USD 631.6 million in 2020, and USD 567.9 million in 2019.

Related Reports:

APAC Infusion Pumps Market by Product (Accessories (Dedicated, Non-dedicated), Devices (Volumetric, Insulin, Syringe, Ambulatory)), Technology (Traditional, Specialty), Application (Cancer, Diabetes), & End User (Hospital, Home Care) - Fore cast to 2027

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]